RecruitingNCT04883905
ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)
Studying Acute hepatic porphyria
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alnylam Pharmaceuticals
- Principal Investigator
- Medical DirectorAlnylam Pharmaceuticals
- Enrollment
- 150 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2027
Study locations (30)
- Clinical Trial Site, Birmingham, Alabama, United States
- Clinical Trial Site, Gilbert, Arizona, United States
- Clinical Trial Site, San Francisco, California, United States
- Clinical Trial Site, Baltimore, Maryland, United States
- Clinical Trial Site, Boston, Massachusetts, United States
- Clinical Trial Site, Minneapolis, Minnesota, United States
- Clinical Trial Site, New York, New York, United States
- Clinical Trial Site, Winston-Salem, North Carolina, United States
- Clinical Trial Site, Oklahoma City, Oklahoma, United States
- Clinical Trial Site, Philadelphia, Pennsylvania, United States
- Clinical Trial Site, Galveston, Texas, United States
- Clinical Trial Site, Salt Lake City, Utah, United States
- Clinical Trial Site, Seattle, Washington, United States
- Clinical Trial Site, Brussels, Belgium
- Clinical Trial Site, Leuven, Belgium
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04883905 on ClinicalTrials.govOther trials for Acute hepatic porphyria
Additional recruiting or active studies for the same condition.